TVM Capital is a venture capital firm that specializes in investments in the life science industry, including biotech, pharmaceuticals, and medical technologies. The company has a long-standing history of providing seed funding, as well as early and later stage financing for innovative companies in the healthcare sector.

TVM Capital

TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care.

TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics.

The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.

Bluebird Bio

Abionyx Pharma

Argos Therapeutics

Arteris

Concert Pharmaceuticals

Definiens

Newron Pharmaceuticals

TME Pharma

Vivoryon Therapeutics

Proteon Therapeutics

Rapid Micro Biosystems

F-Star Therapeutics

TVM Capital Life Science

🚀 Reflecting on an AI Discussion at the LSI USA '24 Emerging Medtech Summit 🚀

Last week's panel Advent of AI: What Will it Take to Drive True Adoption in Clinical Workflows?, moderated by Natasha Allen, Foley & Lardner LLP explored AI’s transformative role in healthcare. Sascha Berger, General Partner at TVM Capital Life Science and other panelists dove into AI's real-world benefits, investment trends and implementation strategies.

 🌐 Highlights:

Clinical Efficiency: Innovations by Vektor Medical, Inc. Medical (TVM portfolio company) and Vista.ai are revolutionizing healthcare workflows, enhancing electrophysiology (EP) lab efficiencies, and making MRIs more accessible.

Real-world Application: Beyond the hype, AI is a practical tool that improves patient care and addresses healthcare workforce shortages.

Investment Growth: The increasing investment in healthcare AI reflects a deeper trust in AI’s capabilities and effectiveness.

Overcoming Challenges: Despite integration hurdles, strategic investments and business models focused on healthcare needs are paving the way for AI’s broader adoption. 

🌟 Takeaway:

The discussion underscored AI's potential to advance healthcare, emphasizing the need for strategic investment and practical implementation strategies. It’s clear that AI is not just a future possibility but a present reality shaping healthcare for the better.

 #HealthcareAI #MedTech #LSIUSA24 #AIInHealthcare #DigitalHealth #LifeScienceInvestment #VC

🚀 Dr. Luc Marengere, will share his expertise and insights at the LSI USA ‘24 Emerging Medtech Summit 2024.

🌟 Don’t miss his panel, “The End of One Road and the Beginning of Another: Transitioning from Pre to Post FDA”. 

This discussion promises to delve deep into the challenges and opportunities that lie in the medtech innovation sphere, especially through the critical phase of FDA approval transitions. It's a unique chance to gain expert insights into how medtech is redefining healthcare standards and what it means for future care.

👉 March 20th | 5:10-5:50pm PST | Track 2

#MedTech #HealthcareInnovation #FDAApproval #HealthTech

🌟 Meet Sascha Berger 🌟, at the LSI USA '24 Emerging Medtech Summit! With his expertise in deal flow generation and pivotal role in recent medtech deals, Sascha will highlight the critical role of AI in healthcare. 

🔍  He will be part of a panel exploring the transformative potential of AI in revolutionizing healthcare, emphasizing the necessity of embracing AI-driven data analysis and technological advancements

👉 March 20th | 1:30-2:10pm PST | Track 3

#Medtech, #HealthTech, #AIinHealthcare, #InnovationInMedicine #FutureOfHealthcare

Revolutionizing Drug Development: A Takeaway from BIO-Europe Spring 2024 🌟

On Day 2 in sunny Barcelona, Hubert Birner engaged in an insightful discussion with Renee T. Williams, PhD MBA, Founder and Managing Partner at Williams Biotech Consulting, LLC, moderated by Emily Mitchell VP, General Partner at ICON plc, highlighting a stark reality: currently about 75% of innovative scientific ideas fail to reach proof-of-concept.

How could our collective mission to improve success rates look?

Two key points:

Collaboration Is Key: 🤝 Success hinges on the dialogue between the asset's originator, VC investors and CROs. Aligning on the strengths each partner brings to the table, common goals and expectations early on is vital.

Leveraging Technology: 💡 The advent of AI and new tech is crucial for boosting clinical development success rates.
 
Our Vision: By fostering strategic partnerships and embracing advanced technologies, TVM Capital Life Science is dedicated to investing in groundbreaking ideas and supporting their transition into clinical realities. 

#BIOEuropeSpring2024 #DrugDevelopment #Innovation

msh id	COM:TVM-CAPITAL
symbol	-
name	TVM Capital
homepage url	https://tvm-capital.com
country	DE
sector	Healthcare & Health Services
industry	Healthcare
market	PRIVATE
employee count	46
crunchbase url	https://www.crunchbase.com/organization/tvm-capital-life-science
linkedin url	https://www.linkedin.com/company/tvm-capital
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	12.67
growth score 28	18.7
growth score 90	16.4
growth score 365	29.46

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:TVM-CAPITAL

TVM Capital

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-